SIRT2 and melanoma: Our previous studies showed that pharmacological inhibition of SIRT2 and stable shRNA-mediated knockdown sensitized melanoma cells to doxorubicin and dasatinib, respectively [6,9], and analysis of transcriptomes revealed that sirtuin 2 is an important regulator of genes involved in melanoma progression and drug resistance (e.g., integrins, tyrosine kinase receptors, MAP kinases, etc.)[9].